Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder
NCT07506395Phase 1Recruiting
- Sponsor
- The University of New Mexico
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in post-traumatic stress disorder (PTSD), sponsored by The University of New Mexico. Primary endpoints: Rate of study completion at 18 weeks, Clinician-Administered PTSD Scale for DSM-5 at 18 weeks and 1 more. Started May 2026; status: recruiting.
02
Drugs
psilocybin
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT07506395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07506395.